Filing Details

Accession Number:
0001140361-18-027475
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-06-05 19:46:45
Reporting Period:
2018-06-01
Accepted Time:
2018-06-05 19:46:45
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1501989 Cytomx Therapeutics Inc. CTMX Pharmaceutical Preparations (2834) 273521219
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1706863 Debanjan Ray C/o Cytomx Therapeutics, Inc.
151 Oyster Point Blvd., Suite 400
South San Francisco CA 94080
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-05-31 1,187 $17.90 5,928 No 5 A Direct
Common Stock Acquisiton 2018-06-01 3,000 $1.26 8,928 No 4 M Direct
Common Stock Disposition 2018-06-01 3,000 $25.93 5,928 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 5 A Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2018-06-01 3,000 $0.00 3,000 $1.26
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
5,710 2023-12-10 No 4 M Direct
Footnotes
  1. The shares were acquired under the issuer's Employee Stock Purchase Plan on May 31, 2018.
  2. The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
  3. This transaction was executed in multiple trades in prices ranging from $25.75 to $26.25, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  4. 100% of the shares subject to the option are fully vested and exercisable.